Editor's Pick

Biden administration to lower costs for 64 drugs through inflation penalties on drugmakers

President Joe Biden’s administration announced a policy proposal aiming to lower drug prices for the American public. The new proposal will enforce inflation penalties on pharmaceutical companies. These penalties will be applicable when companies increase drug prices at an annual rate above that of inflation.

The drugs chosen for this action are among the most expensive treatments and are used by millions of Americans. These drugs include insulin, used for diabetes, and Humira, an immunosuppressant used for conditions like rheumatoid arthritis and Crohn’s disease.

The main purpose of this initiative is to make medications more affordable for those who depend on them, by limiting excessive price increases from manufacturers. This comes as part of the Biden administration’s broader effort to reduce healthcare costs.

However, some critics argue that these penalties may not go far enough, as they do not directly lower the initial price set by drug manufacturers. Nonetheless, this move, once approved, could save the Medicare program billions of dollars.

This plan must still undergo a public comment period before it can be finalized. Please note that this is currently a proposal and is subject to change based on ongoing discussions and revisions.

You May Also Like

Editor's Pick

This statement indicates that despite the increase in the number of people choosing to travel by air, which is creating a record-breaking demand, the...

Editor's Pick

The Federal Trade Commission (FTC) recently announced that it has reached a settlement with drugstore chain Rite Aid over its “improper use of facial...

Editor's Pick

That’s correct. Dollar Tree, the parent company of the budget stores Family Dollar and Dollar Tree, announced in 2019 that it would close nearly...

Economy

It sounds like you’re interested in creating a narrative or story around these characters. Let’s set up how they might interact. — Once upon...

Disclaimer: Financeflowinsider.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2024 financeflowinsider.com

Exit mobile version